AKT1 and ovarian carcinoma: Both SKOV3 and A2780 have hyperactive PI3K/AKT signaling due to mutations in PI3KCA and PTEN, respectively; however, their differential response to MEKi suggests that constitutively active AKT downstream is not prognostic of response to MEKi in ovarian cancer cells.